VitaNova Life Sciences Swings to $54,853 Net Loss in First Nine Months of FY2026

VitaNova Life Sciences Corporation swung to a net loss of $54,853 for the nine months ending January 31, 2026, compared to net income of $50,414 in the same period a year earlier, despite revenue surging 75% to $1.24 million from $708,913. Read more earnings reports.

The Nevada-incorporated life sciences company reported revenue of $709,625 for the three months ending January 31, 2026, up 130% from $308,318 in the prior-year quarter. For the nine-month period, revenue reached $1.24 million, with the bulk coming from product sales of $1.23 million and consulting revenue of $15,000.

Margins Compress as Costs Outpace Revenue Growth

Cost of revenue jumped 105% to $594,712 for the nine-month period from $290,594 a year earlier, eroding gross profit to $645,927 from $418,319. Gross margin fell to 52% from 59% in the prior-year period.

Operating expenses climbed 82% to $532,466 from $292,259, driven by higher labor costs of $124,228 and administrative expenses. For the quarter ending January 31, 2026, operating expenses reached $269,612, up from $80,438 in the same quarter last year.

Operating income for the nine months totaled $113,461, down 10% from $126,060 a year earlier. The company reported operating income of $46,731 for the third quarter, compared to $108,874 in the prior-year quarter.

Third Quarter Turns Negative

The company posted a net loss of $44,362 for the three months ending January 31, 2026, a sharp reversal from net income of $72,978 in the same quarter last year. Income tax expense for the quarter totaled $91,093 compared to $35,279 in the prior-year period.

For the nine-month period, income tax expense reached $168,434 versus $73,204 a year earlier. The company reported no interest expense for the nine months ending January 31, 2026, compared to $2,938 in the prior-year period.

Balance Sheet and Cash Position

Total assets stood at $2.31 million as of January 31, 2026, up from $2.26 million at the end of fiscal 2025. Cash and restricted cash rose to $1.17 million from $782,810 at the fiscal year-end on April 30, 2025.

Accounts receivable declined to $1.00 million from $1.27 million, while inventory increased to $130,436 from $44,247. Total liabilities climbed to $457,975 from $347,567, with accounts payable rising to $108,978 from zero at fiscal year-end.

Stockholders' equity decreased to $1.85 million as of January 31, 2026, from $1.91 million at April 30, 2025. Retained earnings fell to $812,848 from $867,701.

The company generated cash from operations of $386,094 for the nine months ending January 31, 2026, a reversal from negative cash flow of $286,363 in the prior-year period. The company reported no financing activity in the current period, compared to $98,500 raised in the prior year.

Per Share Results

Basic and diluted loss per share for the nine months ending January 31, 2026, came to negative $0.01, compared to earnings of $0.01 per share a year earlier. The company had 8,337,454 weighted average shares outstanding for both basic and diluted calculations.